BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 25617503)

  • 1. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
    Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
    J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
    Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
    Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
    Wang S; Sheng F; Zou L; Xiao J; Li P
    J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
    Fujita K; Iguchi Y; Une M; Watanabe S
    Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity.
    Gonzalez FJ; Jiang C; Bisson WH; Patterson AD
    J Hepatol; 2015 Jun; 62(6):1234-6. PubMed ID: 25747705
    [No Abstract]   [Full Text] [Related]  

  • 6. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model.
    Taylor R; Yang Z; Henry Z; Capece G; Meadows V; Otersen K; Basaly V; Bhattacharya A; Mera S; Zhou P; Joseph L; Yang I; Brinker A; Buckley B; Kong B; Guo GL
    Toxicol Sci; 2024 May; 199(2):316-331. PubMed ID: 38526215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
    Carulli N; Ponz De Leon M; Zironi F; Pinetti A; Smerieri A; Iori R; Loria P
    J Lipid Res; 1980 Jan; 21(1):35-43. PubMed ID: 7354253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis.
    Ling CJ; Xu JY; Li YH; Tong X; Yang HH; Yang J; Yuan LX; Qin LQ
    Food Funct; 2019 Nov; 10(11):7299-7307. PubMed ID: 31626262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues.
    Watanabe S; Fujita K
    Lipids; 2014 Oct; 49(10):963-73. PubMed ID: 25189147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
    Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
    Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-Theanine regulates lipid metabolism by modulating gut microbiota and bile acid metabolism.
    Xu W; Kong Y; Zhang T; Gong Z; Xiao W
    J Sci Food Agric; 2023 Feb; 103(3):1283-1293. PubMed ID: 36087337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
    Mueller M; Castro RE; Thorell A; Marschall HU; Auer N; Herac M; Rodrigues CMP; Trauner M
    Liver Int; 2018 Mar; 38(3):523-531. PubMed ID: 28853202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
    Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
    Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
    Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.